Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 trial to study the effect of SY-1365 for the treatment of patient with acute leukemia

Trial Profile

A Phase 1/2 trial to study the effect of SY-1365 for the treatment of patient with acute leukemia

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 23 May 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mevociclib (Primary)
  • Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Syros Pharmaceuticals

Most Recent Events

  • 15 May 2017 Syros plans to initiate this trial based on the data from other trial (see profile 279117), as reported in a company media release.
  • 26 Apr 2016 New trial record
  • 20 Apr 2016 According to a Syros Pharmaceuticals media release, company plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in the second half of 2016 with the goal of initiating this study in acute leukemia in the first half of 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top